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Abstract
Magnetic resonance imaging (MRI) has been utilized for
screening and detecting brain tumors in mice based
upon their imaging characteristics appearance and their
pattern of enhancement. Imaging of these tumors
reveals many similarities to those observed in humans
with identical pathology. Specifically, high-grade mur-
ine gliomas have histologic characteristics of glioblas-
toma multiforme (GBM) with contrast enhancement
after intravenous administration of gadolinium dieth-
ylenetriamine pentaacetic acid (Gd-DTPA), implying
disruption of the blood–brain barrier in these tumors. In
contrast, low-grade murine oligodendrogliomas do not
reveal contrast enhancement, similar to human tumors.
MRI can be used to identify mice with brain neoplasms
as inclusion criteria in preclinical trials.
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Introduction
The use of mouse models for human cancer in preclinical
trials requires the identification of mice with tumors and
quantitation of their tumor size for stratification, measure-
ments of growth rate, and treatment response. In the case of
mouse models for brain tumors, the identification of mice with
tumors is complicated because of the inability to detect their
presence because of their location within the cranial cavity.
The development of noninvasive imaging techniques is
necessary for maximizing the information available from
these novel models.
In humans, low-grade gliomas are typically seen as areas
of hypointense signal on T1 (spin–lattice relaxation time)–
weighted scans and hyperintense signal on T2 (spin–spin
relaxation time)–weighted scans, and do not enhance with
gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA)
[1–3]. The biological properties that correlate with these
imaging characteristics are proposed to be an intact blood–
brain barrier and edema surrounding the tumor cells. In
contrast, glioblastomas reveal marked contrast enhancement
indicating a disrupted blood–brain barrier, and nonenhancing
regions within the tumor that correlate with foci of necrosis
[1–3]. Therefore, magnetic resonance imaging (MRI) is
used to identify the presence of these tumors, to follow their
response to therapy, and to provide evidence of residual or
recurrence of disease.
MRI has been used to examine experimental brain tumors
in rodents in diverse models [4–10]. Many of these studies
utilized T1- and T2-weighted imaging techniques [4–6,8],
which were found to be quantitative based upon phantom
studies [6]. More recently, diffusion-weighted imaging has
been added in brain tumor studies [9,10]. Chenevert et al.
[5,9] suggested that diffusion-weighted imaging could
provide a surrogate marker for treatment response in patients
based upon rodent tumor studies. MRI and magnetic reso-
nance spectroscopy (MRS) have also been used to study
other tumor models and to provide metabolic and anatomic
information [11–15]. Other imaging modalities including
optical imaging [16–20], computed tomography [21], and
radionuclide imaging have also been used to study rodent
tumors [22–25].
MRI can be utilized to screen and identify mice harboring
brain tumors, and the imaging characteristics of the tumors
could potentially be used as one criterion of efficacy for
strategies being developed and tested. In order to use such
technology in this manner, baseline investigations correlating
the imaging properties of brain tumors in mice with their
histologic properties are necessary. Subsequent studies to
determine how the tumor and its physiological parameters
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have changed in response to treatment need to be done
noninvasively. In order to perform such studies, mouse
modeling systems that generate tumors with defined
histologies mimicking human gliomas are required.
The RCAS/tv-a system has been used to generate
several glioma types that are similar both in histology and
genetics to that found in humans. This system utilizes avian
RCAS retroviral vectors that transfer genes to mammalian
cells only if they express the receptor for RCAS known as
TVA [26]. TVA is not normally expressed inmammals but can
be expressed as a transgene from tissue-specific promoters
in transgenic mice. Two transgenic mouse lines that express
tv-a from the nestin promoter (Ntv-a) [27] and the GFAP
promoter (Gtv-a) [28] to support gene transfer into glial
progenitors and astrocytes, respectively, have been used.
Oligodendrogliomas in this model are generated by
transfer of platelet -derived growth factor (PDGF) to glial
progenitors, generating an autocrine loop [29]. These PDGF-
induced gliomas are predominantly low grade and show all
the histological characteristics of oligodendrogliomas in
humans including the classic ‘‘chicken wire vasculature’’
and invasion of adjacent normal brain structures. In contrast,
the simultaneous activation of Ras and Akt signaling path-
ways in these same glial progenitors leads to the formation of
tumors with histologic appearance of glioblastoma multi-
forme (GBM) [30]. These tumors reveal regions of nuclear
pleomorphism, pseudopalisading necrosis, and microvascu-
lar proliferation.
The object of this study is to demonstrate that the MRI
characteristics of the low- and high-grade gliomas in mice
are similar to the equivalent human gliomas. Furthermore,
the ability of MRI to identify mice with large gliomas for
inclusion in preclinical trials is demonstrated.
Methods
The generation of the Ntv-a and Gtv-a mice has been
described [27,28]. Ntv-a mice were infected at birth with
RCAS vectors by intracranial injection of 1 l of 104 DF-1
cells infected with and producing RCAS retroviral vectors,
which has been previously described [27]. The mice were
then observed for signs of intracranial pathology such as
macrocephaly or lethargy. Such mice were anesthesized by
the use of isoflurane and placed in the single mouse coil.
Single Mouse Imaging
Images were obtained on a 1.5-T General Electric LX
Echo Speed Signa scanner (General Electric Medical
Systems, Milwaukee, WI). Single animal images were
obtained using a 2.9-cm- inner-diameter (7 cm in length),
low-pass bird cage coil operating in quadrature and tuned
to 63.9 MHz, specifically designed for mice studies (courtesy
of Dr. Boskamp; General Electric Medical Systems). This
coil was interfaced with the head coil port on the Signa
system with an additional attenuation of 36 dB at the
transmitter output. T1-weighted images {TR (repetition
interval )=450 ms, TE (echo time)=9 ms} and T2-weighted
images {FSE ( fast spin echo), TR=4 s, TE=85 ms, and
echo train length (ETL)=8} were obtained prior to intracar-
diac contrast administration and T1-weighted images were
obtained immediately after contrast injection (0.2 mM/kg).
Acquisition parameters included a field of view (FOV) of
4 cm, slice thickness of 0.5–1 mm, and a matrix size of
256256 ( in-plane resolution of 156156 m). Mice were
anesthesized with isoflurane for these studies. Four mice
from each category (Ras+Akt - induced GBMs, PDGF-
induced low-grade oligodendrogliomas, high-grade PDGF-
induced oligodendrogliomas) were studied.
Multiple Mouse Imaging
For screening larger numbers of mice, a parallel wound
foil solenoid coil (Xu et al., submitted for publication) was
used. In brief, the coil is a three- turn parallel wound foil
solenoid (86 mm in diameter ) designed for screening 13 to
15 mice simultaneously. This coil was interfaced directly to
the Signa and required 20 dB of transmitter attenuation. Prior
to study, a 24-gauge catheter was placed in the mouse tail
vein. Subsequently, the mice were anesthesized and placed
in the coil. Set-up time included approximately 5 to 10 min
per mouse for tail vein catheterization and approximately
15 min for anesthesizing the mice subsequently and placing
in the coil. The imaging protocol included sagittal scout
Figure 1. T2 - and T1 -weighted (pre - and postcontrast ) images from a mouse with hydrocephalus. The hyperintense signal in the T2 -weighted images reflect the
dilated lateral ventricles. Areas of hydrocephalus have high signal intensity on T2 - and low signal intensity on T1 -weighted image, reflecting the higher T1 and T2
values of fluid. Note the lack of enhancement postcontrast.
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images followed by axial scout T2-weighted images, which
each required less than 1 min. These were followed by high-
resolution T2-weighted images, followed by a precontrast
T1-weighted image. Subsequent to the contrast adminis-
tration (0.2 mm/kg Gd-DTPA), T1-weighted images were
obtained. The typical imaging parameters for T2-weighted
images included a slice thickness of 1.5 mm and an in-plane
resolution of 156333 m (FOV of 8 cm and an imaging
matrix of 512256), TR=4 to 6 s, TE=102 ms, an ETL of 16,
and six excitations per phase-encoding step ( imaging time
of 6.4–9.6 min). On occasion, higher resolution scans
(512512) were obtained, which required longer acquisition
times (up to 20 min). For T1-weighted images, the typical
imaging parameters included a slice thickness of 1.5 mm and
an in-plane resolution of 333417 m (FOV of 8 cm and an
imaging matrix of 256192), TR=300 ms, TE=9 ms, and
three excitations per phase-encoding step ( typical imaging
time of approximately 2.9 min). Mice were anesthesized with
ketamine (90 mg/kg) and xylazine (9 mg/kg) intraperito-
neally for these studies. The total time in the magnet was
about 35 to 40 min.
Results
Mice Developing Ras+Akt- Induced GBMs
Seventy percent of human GBMs show substantially
elevated signaling through the Ras and Akt pathways [30].
These alterations appear to be responsible for the develop-
ment of GBMs because activation of these pathways in mice
results in the formation of gliomas with similarity to human
GBMs. These mice were generated by intracranial injection
of Ntv-a transgenic mice with the combination of DF-1
producer cells, generating RCAS-Ras and RCAS-Akt
vectors. Approximately 20% to 30% of these transgenic
mice develop gliomas. Mice with gliomas can be identified by
the development of symptoms such as lethargy, hunched
posture, weight loss, and poor grooming. However, these
mice may also develop hydrocephalus that may or may not
be associated with tumor development, and mice with hydro-
cephalus also develop similar symptoms. Figure 1 presents
an image of a mouse with severe hydrocephalus. This is
readily recognized as a bright area on T2-weighted images
that does not enhance after Gd-DTPA.
Figure 2. Images and histopathologic sections of brain tumor obtained by infecting Ntv - a mice with combined RCAS-Ras and RCAS-Akt vectors. Images obtained
with single mouse coil. ( A ) Intracranial tumor exhibits hyperintense signal on T2 -weighted images and on postcontrast T1 -weighted images. (B ) Whole mount
section corresponding to the images obtained by MRI. (C ) Microscopic images of the GBM show histologic similarities to GBMs in humans.
Figure 3. Images and histopathologic sections of a brain tumor obtained by infecting Ntv - a mice with RCAS-PDGF. (A ) Pre - and postcontrast MRI with lack of
enhancement in the tumor region. (B ) Corresponding whole mount brain section. (C ) Microscopic histology of this tumor consistent with an oligodendroglioma.
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In order to determine if the imaging characteristics of
GBMs developing in mice are similar to that seen in humans,
Ntv-a mice were infected with combined RCAS-Ras and
RCAS-Akt vectors. Several of these mice developed symp-
toms consistent with the presence of intracranial gliomas.
These mice were anesthesized with isoflurane and imaged
using the single mouse coil to demonstrate the presence of
tumor. As illustrated in Figure 2A, intracranial tumors were
readily identified by imaging on T1-weighted images post
Gd-DTPA. These tumors enhanced with gadolinium con-
trast as seen in human GBMs, indicating disruption of the
blood–brain barrier.
These mice were immediately sacrificed and the brains
fixed in formalin. The brains were sectioned in the same
plane to the MRI (Figure 2B ). Pathological evaluation
revealed nuclear pleomorphism, microvascular proliferation,
pseudopalisading, and necrosis similar to the human GBM
(Figure 2C ).
PDGF-Induced Low-Grade Oligodendrogliomas
Ntv-a mice were infected with RCAS-PDGF as has been
described [29]. These mice develop low-grade oligoden-
drogliomas. Mice developing intracranial symptoms were
identified and scanned as described above using the single
mouse coil (Figure 3A ). These lesions do not enhance
with intravenous contrast. As in the mice with GBMs, the
mouse was sacrificed immediately after imaging and the
brain was fixed and sectioned parallel to the plane of imaging
(Figure 3B ). Pathological evaluation revealed an oligoden-
droglioma including regular round nuclei, cleared cytoplasm,
and lack of immunohistochemical staining of tumor cells with
antibodies to the astrocytic marker glial fibrillary acetic
protein.
High-Grade PDGF-Induced Oligodendrogliomas
High-grade gliomas in humans frequently have deletions
in the INK4a-ARF tumor suppressor gene and therefore do
not express either p16INK4a or p14ARF tumor suppressor
gene products that control cell cycle arrest. PDGF- induced
gliomas in mice with a targeted deletion of INK4a-ARF have
the propensity to show high-grade characteristics such as
microvascular proliferation, and pseudopalisading necrosis
has been previously demonstrated. Therefore, Ntv-a
INK4a-ARF / mice were infected with RCAS-PDGF.
Mice developing symptoms were identified and scanned as
above, with findings illustrated in Figure 4. A portion of the
lesion enhanced after administration of intravenous contrast.
Comparison with the whole mount demonstrates that these
enhancing regions correspond to areas of higher cellular
density and necrosis. Histological analysis of the vasculature
of the enhancing and nonenhancing regions of the tumors
showed other parallels with the human disease. The
Figure 4. Images and histopathologic sections of brain tumor obtained by infecting Ntv -a INK4a -ARF /  mice with RCAS -PDGF. (A ) Pre - and postcontrast
MRI demonstrating lesion enhancement post Gd -DTPA (arrow ). (B,C ) Whole mount of the section shown in (A ) revealing that the enhancing region has higher
cellular density and necrosis.
Figure 5. Histologic analysis of the vasculature of the enhancing and nonenhancing regions of the tumor from Figure 4. (A ) Nonenhancing regions of tumor have
‘‘chicken wire’’ vasculature ( arrow ) seen in human low -grade oligodendrogliomas. (B ) Regions of tumor that enhanced with gadolinium showed glomeruloid
microvascular proliferation similar to that seen in high grade oligodendrogliomas.
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nonenhancing regions of tumor demonstrated the chicken
wire vasculature seen in human low-grade oligodendroglio-
mas (Figure 5A ). By contrast, the regions of tumor that
enhanced with gadolinium showed glomeruloid microvascu-
lar proliferation similar to that seen in high-grade gliomas
(Figure 5B ). Therefore, the regions of enhancement within
this diffuse tumor correlate with high-grade histology and
similar vascular abnormalities as seen in the human disease.
Obtaining Images on Multiple Mice with Possible
Gliomas Simultaneously
In order to determine if the multimouse imaging coil would
be able to identify mice harboring gliomas within a population
of mice, Ntv-a mice that had been infected with the
combination of RCAS-Akt and RCAS-Ras were screened.
Mice that had developed symptoms described above were
anesthesized and imaged. Figure 6A shows a T2-weighted
scan, which shows seven mice in the plane of the image.
Two of these mice had findings suggestive of a brain tumor.
In addition to being detected on the T2-weighted image, the
tumors are readily distinguished from the high signal intensity
areas seen with hydrocephalus. The T1-weighted pre- and
postcontrast images, respectively, reveal, as in the clinical
situation, contrast enhancement after Gd-DTPA injection
(0.2 mm/kg) on T1-weighted images. These images
demonstrate the feasibility of successfully screening mice
quickly using medium resolution images and very sensitive
solenoid coils to detect mice that develop brain tumors.
To evaluate the contrast between normal brain and tumor,
the ratio of signal intensity of tumor versus brain was
measured. The T2-weighted images had a tumor /brain
signal intensity ratio of 1.003±0.06 (mean±SEM). For T1-
weighted images precontrast administration, the ratio was
1.13±0.10. For T1-weighted images postcontrast, the ratio
was 13.35±1.51, which was highly significant (P<.001).
Low-grade gliomas failed to enhance, indicating that MRI
can distinguish high-grade gliomas and distinguish between
high- and low-grade gliomas.
Discussion
Animal modeling of cancer formation allows not only the
identification of causative factors in tumor formation but also
provides tumor-bearing animals for the testing of exper-
imental therapeutics [31]. The use of mice with tumors
identified by imaging techniques in preclinical trials allows
each mouse to be used as its own control and substantially
expands the information that can be obtained from such
trails. In the absence of imaging data, population studies
requiring large numbers of mice need to be undertaken. If
one estimates that 20% of the mice have tumors and a cohort
size of 6 to 10 tumor-bearing mice is necessary for eva-
luating a treatment, one can reduce the size of each cohort
from 30–50 to 6–10 mice by using imaging to identify
appropriate mice.
Many new imaging techniques that help distinguish
various characteristics of tumors are being developed.
However, in humans, the pathological correlation among
the image, the genetics, and the histology is often not
possible. The combination of imaging techniques and animal
models for gliomas will allow such correlations and not only
validate the models as similar to the human disease, but also
validate the imaging techniques as representing the pathol-
ogy proposed.
The development of novel transgenic and knockout mice,
which do not predictably develop tumors with 100%
penetrance, emphasizes the need for a screening technique.
MRI, either at high spatial resolution or even at moderate
resolution such as obtained with the coil used for multiple
mouse imaging, has the potential to address this need using
moderate spatial resolution scans as demonstrated. Despite
the loss of some spatial resolution compared to other
techniques, detection of these tumors is quite easy because
they are visualized on T2-weighted images and also on T1-
weighted (postcontrast ) studies. The amount of magnet time
necessary for studying 13mice is about 40 min. Conceivably,
one could forego the T2-weighted images (6–10 min)
because the postcontrast T1-weighed images are ‘‘diag-
Figure 6. Images obtained on Ntv - a mice that had been infected with the combination of RCAS -Akt and RCAS-Ras. Plates (A ), (B ), and (C ) are T2. T1
(precontrast ) and T1 (postcontrast ) from a single slice of multiple mice. Arrows indicate tumor as seen best on post Gd -DTPA images. Areas of hyperintense signal
in the T2 -weighted images correspond to areas of hydrocephalus, which are noted to not enhance with Gd -DTPA. Acquisition parameters included TR=5500 ms,
TE=102 ms, NEX=4, 512512, 88 cm2, slice thickness=1.5 mm, gap=0.5 mm.
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nostic’’ and would allow one to screen up to about 26 mice in
an hour. We estimate that we can screen about 150 mice per
day based on these imaging times, which should be
adequate to meet the needs of most experimental research
groups. It is likely that this will represent an upper limit or
even slight overestimate because it is expected that some
mice might be restudied at higher spatial resolution if there
are areas that are suspicious for small tumors. The times
required for catheter placement, anesthesia, and placing the
mice in the coil are not significant because the limiting
resource is magnet time and these activities occur while
other mice are undergoing study. We have been able to
detect tumors as small as 0.8 mm in axial diameter, although
with tumors less than 1 mm diameter, some lesions were
missed ( three of eight tumors smaller than 1 mm were
detected). All tumors greater than 1.5 mm in diameter (n=9)
were detected.
These imaging systems are currently in use in preclinical
trials of small molecule inhibitors of signal transduction path-
ways. These systems provide the ability to look at immediate
responses at the imaging, histologic, and genetic levels to
disruption of the pathways that induce gliomas.
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